肿瘤相关巨噬细胞与PD-1/PD-L1在胃癌免疫治疗中的现状与前景

Current status and future prospects of tumor-associated macrophages and PD-1/PD-L1 in gastric cancer immunotherapy

胃癌是常见的恶性肿瘤之一,发病率和死亡率均较高。近年来,程序性死亡蛋白-1(PD-1)/程序性死亡蛋白配体-1(PD-L1)抑制剂因其良好的疗效,迅速成为胃癌的治疗方法之一。值得注意的是,近年来研究发现肿瘤微环境在癌症进展中也起着关键作用。肿瘤微环境中最丰富的细胞群体是肿瘤相关巨噬细胞,它们能表达PD-1,并且可以与癌细胞表面的PD-L1形成配体。因此,肿瘤相关巨噬细胞可能影响PD-1/PD-L1抑制剂在胃癌治疗中的效果,但目前相关研究较少,其作用机制尚不明确。该文对当前的相关研究进行整理、总结,以期能为胃癌病人的治疗提供更多的选择。

Gastric cancer(GC)is a common malignant tumor with a high incidence and elevated mortality rate.In recent years,PD-1/PD-L1 immune checkpoint inhibitors have rapidly become one of common treatments for GC due to their superior efficacy.Notably,recent studies have highlighted the critical role of tumor microenvironment in cancer progression.Among various cell types present in the tumor microenvironment,tumor-associated macrophages(TAMs)are the most abundant.These macrophages can express PD-1 and interact with PD-L1 on the surface of cancer cells.Therefore TAMs may influence the therapeutic effectiveness of PD-1/PD-L1 immune checkpoint inhibitors for GC.However,there are few current researches on this topic and the underlying mechanisms have remain elsuive.This review summarized the latest researches to provide more treatment options for GC patients.